Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy.
BACKGROUND
The liver is the most frequent site of metastases from colorectal cancer (CRC), and extensive liver metastases often cause severe secondary liver dysfunction. However, whether chemotherapy for metastatic CRC with severe liver dysfunction offers any clinical benefit is unclear since patients in this setting are typically excluded from clinical trials.


CONCLUSIONS
We report herein a case of metastatic sigmoid colon cancer with severe liver dysfunction that was successfully treated using infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX). FOLFOX was effective and well tolerated in the present case, and subsequent addition of bevacizumab to FOLFOX after disease progression was similarly feasible.
Shimura
Takaya
T
Kataoka
Hiromi
H
Hirata
Yoshikazu
Y
Mizushima
Takashi
T
Murakami
Kenji
K
Mabuchi
Motoshi
M
Mizoshita
Tsutomu
T
Kubota
Eiji
E
Tanida
Satoshi
S
Kamiya
Takeshi
T
Joh
Takashi
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D017093:Liver Failure / Q000188:drug therapy* / Q000209:etiology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil